Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-1 for immunologic non-response in HIV/AIDS patients on suppressive ART
ChiCTR-IIR-17012045Phase 2Not yet recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ZL-1 in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS) (2 arms), sponsored by Shanghai Public Health Clinical Center. Primary endpoint: Percent of patients with CD4+ T-cell increase of at least 30%. Planned start May 2017; status: not yet recruiting.
02
Drugs
ZL-1
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ChiCTR-IIR-17012045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012045.